Bankrupt Savient Gets OK For $120M Sale To Crealta

Law360, Wilmington (December 13, 2013, 6:34 PM EST) -- A Delaware bankruptcy judge on Friday blessed drug developer Savient Pharmaceuticals Inc.'s sale to Crealta Pharmaceuticals LLC for $120.4 million, more than twice the price initially established by the debtor's stalking horse bidder.

Savient entered court protection two months ago with a US WorldMeds LLC subsidiary in place as a $55 million stalking horse for planned auction, and the Section 363 process produced a “remarkable success,” Savient attorney David Turetsky said Friday at a sale hearing in Wilmington.

The auction, held Tuesday, featured four bidders and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.